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Abstract. A water-soluble extract from the culture medium
of Ganoderma lucidum (Rei-shi) mycelia (MAK) has been
shown to exert a potent chemopreventive effect. The present
study was designed to investigate the effects of dietary MAK
supplementation on the development of lung tumors initiated
by N-nitrosobis (2-hydroxypropyl) amine (BHP) in male
Slc:Wistar rats. A total of 77 animals, 6 weeks of age, were
divided into 5 groups and given BHP (2,000 ppm) in their
drinking water for 10 weeks. The normal controls were not
supplied with BHP. After treatment with the carcinogen, the
rats were fed a normal control MF solid diet, or the same diet
containing MAK (1.25%, 2.5% or 5%) for 12 weeks. Macro-
scopically, all the doses of MAK reduced the number of
nodules, and the effect of 5% MAK was found to be especially
significant. Microscopically, an increase in the number of
proliferating cell nuclear antigen (PCNA)-negative tumors
and a decrease in the number of tumors strongly positive for
PCNA were observed in the tissue sections from the rats that
had received all the doses of MAK. The present results thus
indicate that dietary supplementation with MAK inhibits the
development of lung tumors, suggesting that MAK may be a
potent chemopreventive agent against lung carcinogenesis.
Introduction
Ganoderma lucidum (Fr.) Karst. (Polyporaceae) is a
medicinal mushroom known to the Japanese as Rei-shi or
Mannentake, or to the Chinese as ‘Lingzhi’. Its fruiting
bodies have been used for their medicinal properties in
traditional Chinese medicine for over 2000 years. This
mushroom is described in detail in the Chinese classics,
Shen Nung Ben Cao Jin (dated 206 BC - 8 AD), and the
Compendium of Ganoderma lucidum has been used in
traditional Chinese medicine for the promotion of vitality and
longevity, and within the present decade for the treatment of
debility and weakness, hypertension, cardiovascular disease,
bronchitis, arthritis, neurasthenia, insomnia, hepatopathy,
chronic hepatitis, nephritis, gastric ulcers, asthma, diabetes,
altitude sickness, AIDS, and cancer (1-3), in China and other
oriental countries. The mycelia of Ganoderma is consumed
as health food and herbal medicines. Chemical investigations
of the fruiting bodies, spores, and the mycelia of Ganoderma
lucidum have shown that they contain various bioactive
substances, including polysaccharides, proteins, nucleosides,
fatty acids, terpenoids, sterols, and cerebrosides (4). Water or
alcohol extracts of Ganoderma lucidum have been used to
investigate biological activities, as these extracts contain
compounds with immunological and anti-inflammatory
properties. Of particular interest among the reported
biological/pharmacological properties of Ganoderma
lucidum are their anti-tumor activities, including cell cycle
arrest, apoptosis induction, motility inhibition, antiangio-
genesis, and antimutagenesis (3,5-10).
A water-soluble extract from the culture medium of
Ganoderma lucidum (Rei-shi) mycelia (MAK) contains
various kinds of high-molecular-weight constituents, such as
polysaccharides with protein or water-soluble lignin, and
low-molecular-weight constituents, such as triterpenes. We
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have reported previously that MAK prevented the development
of azoxymethane-induced aberrant crypt foci and colon
tumors in F344 rats (11,12), and N,N'-dimethyl-hydrazine-
induced colon tumors in ICR mice (13).
To determine whether MAK may exert a chemo-
preventive effect on the carcinogenesis of organs other than
the colon, the present study was conducted assessing the
effects of MAK on the development of rat lung tumors after
initiation with BHP.
Materials and methods
Animals. Seventy-seven 6-week-old male Slc:Wistar rats
(SLC Japan Inc., Hamamatsu, Japan) were used in the
present study. They were housed three or four to a poly-
carbonate cage and kept under constant temperature conditions
(24±2˚C) and relative humidity (55±10%) with a 12 h light/
dark cycle. The animals were maintained in accordance with
the ‘Guidelines for the Care and Use of Laboratory Animals’
established by Hiroshima University and fed a commercial
MF diet (Oriental Yeast. Co. Ltd., Tokyo, Japan) alone or
with a 1.25%, 2.5% or 5% supplement of MAK. Normal tap
water was also provided ad libitum.
BHP. The carcinogen was purchased from Nakarai Tesque
Co. Inc., Kyoto, Japan, and dissolved in distilled water at a
concentration of 2,000 mg/l just before use. This solution
was supplied to the rats ad libitum for 10 weeks from light-
opaque bottles exchanged at 2- or 3-day intervals.
MAK. A water-soluble extract from the culture medium of
Ganoderma lucidum mycelia (designated as MAK) was
prepared by Noda Shokkin-Kogyo Co., Ltd. (Chiba, Japan).
In brief, Ganoderma lucidum (Rei-shi or Mannnentake)
mycelia were cultured in a solid medium composed mainly
of sugar-cane bagasse for three months, then the whole
medium containing the mycelia was extracted with hot water.
The extract was filtered and spray-dried to obtain MAK.
Pathology. The animals were sacrificed and necropsied if
they became moribund, and all the remaining rats were
sacrificed 22 weeks after the BHP treatment. The lungs were
removed and the location and size of the individual tumors
was recorded. All the tissues were fixed in 10% neutral
formalin. Lesions in the lung were classified into four types:
Hyperplasia, adenoma, adenocarcinoma, and squamous cell
carcinoma. Data indicate both the total number of tumors and
the average diameter of the tumors measured in each section
of five lobules.
Immunohistochemistry. Paraffin-embedded sections were
deparaffinized in xylene, and rehydrated through a graded
ethanol series. A 0.05 M PBS buffer was used to prepare the
solutions and also for the washes between the various steps.
The incubations were performed in a humidified chamber.
Three-micrometer-thick sections were treated for 30 min at
room temperature with 2% BSA and incubated with primary
antibodies against ß-catenin (diluted 1:100; Transduction
Laboratories, BD 610153, KY, USA), monoclonal mouse
anti-proliferating cell nuclear antigen antibody (Dako-PCNA,
PC 10, code No. M 879), monoclonal mouse anti-cyclo-
oxygenase-1 (diluted 1:50; Santa Cruz Biotechnology, sc-1754)
and monoclonal mouse anti-cyclooxygenase-2 (diluted
1:100; Santa Cruz Biotechnology, sc-1746) for 1 h at room
temperature. For each case, negative controls were performed
on serial sections whereby incubation with the primary
antibody was omitted. All the slides were then exposed to the
secondary antibody, biotinylated horse anti-universal-monkey
IgG (Vectastain Universal Quick Kit, Vector Laboratories,
CA, USA, Catalog No PK-8800) and peroxidase-conjugated
streptavidin complex. Peroxidase activity was visualized by
treatment with H2O2 and diaminobenzidine for 5 min. At the
final step, the sections were counterstained with hematoxylin
for 1 min. ß-catenin-positive nuclei were counted and divided
by the total epithelial cells in the tumors to give an index for
nuclear accumulation. The PCNA index was classified into
four types: -, Negative (0%); ±, slightly positive (<50%); +,
positive (<80%); ++, strongly positive (>80%). The PCNA
index was calculated from the intensity of PCNA staining of
100 randomly selected tumors in sections of five lobules.
Statistical significance. Statistical significance was determined
using Dunnett's method for multiple comparisons, the ¯2 and
the Student's t-test.
Results
The intake of drinking water in the BHP treatment groups
(6.7 to 7.1 ml/day/animal) was significantly decreased as
compared with the normal controls (18.5 ml/day/animal) but
there was no significant difference among the BHP treatment
groups. The diet intake also showed no significant difference
among the experimental groups after BHP treatment (data not
shown).
All of the animals survived until the scheduled time of
sacrifice. Body weight in the BHP alone group was signifi-
cantly decreased as compared with the normal value (P<0.01)
(Table I). In the BHP alone group, thyroid weight was
significantly increased relative to the control (P<0.01),
and the weight of the liver, testis and adrenal gland was
significantly decreased. The relative weight of the thyroid was
significantly increased as compared with the normal control
value, whereas that of the lung and testis was significantly
decreased (Table I).
Macroscopically, BHP-treated animals had many lung
nodules. Both the number of nodules in the animals given
BHP+5% MAK and the mean diameter of nodules in all the
MAK groups were significantly decreased in comparison
with the corresponding values in the BHP alone group
(P<0.01) (Table II).
Microscopically, as shown in Fig. 1, lesions in the lung
were classified into four types: Hyperplasia, adenoma, adeno-
carcinoma, and squamous cell carcinoma. BHP-treated animals
had pulmonary hyperplasia, adenoma and adenocarcinoma,
and also thyroid tumors. Squamous cell carcinomas were also
evident in 13%, 6%, 20% and 0% of the animals in the BHP,
BHP+1.25% MAK, BHP+2.5% MAK and the BHP+5%
MAK groups, respectively (Table III). The numbers of
pulmonary tumors and adenomas in all the MAK groups and
adenocarcinomas in the BHP+2.5% MAK and BHP+5%
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MAK groups were significantly decreased in comparison
with the BHP alone group (Table IV). The total size of
pulmonary tumors and adenomas in the BHP+5% MAK
group was also significantly lower than that in the BHP alone
group (P<0.01) (Table V).
As shown in Fig. 2, the PCNA index was classified into
four types: -, Negative (0%); ±, slightly positive (<50%); +,
positive (<80%); ++, strongly positive (>80%). The PCNA
indices in the pulmonary tumors are shown in Table VI. The
numbers of PCNA-negative tumors in the BHP+2.5% MAK
and BHP+5% MAK groups were significantly increased. In
the BHP+5% MAK group, the numbers of both positive
tumors and strongly positive tumors were significantly
decreased in comparison with the BHP alone group. None of
the lung tumors showed any nuclear or cytoplasmic staining
for ß-catenin, COX-1 or COX-2.
Discussion
In the present study, MAK did not affect the incidence of
tumors, but significantly reduced the number and size of
tumors in a dose-dependent manner. There are two interesting
reports of studies carried out using a similar animal model of
lung carcinogenesis. One involved long-fermented miso, a
natural product, which did not affect the incidence or size of
tumors, but significantly reduced the number of tumors (14).
The other report describes that a combination of an anti-
biotic, erythromycin, or an anti-inflammatory drug, ampicillin,
with a natural product, sho-saiko-to, decreased the incidence,
size and number of tumors (15). However, as in the case of
MAK and/or miso, the natural product alone did not affect
tumor incidence. Drugs used for cancer chemotherapy are
known to cause undesirable side-effects. In contrast however,
even though natural products possess a less potent anti-tumor
effect than chemical compounds, they are superior in terms
of safety. MAK, being a natural product, could be useful
when used in combination with a chemical compound to
slow the progression of tumor growth. However, further
studies on the application of natural products are warranted.
Yun et al reported that a total extract of the whole fruiting
body of Ganoderma lucidum inhibited the incidence of
pulmonary adenoma induced by benzo(a)pyrene (BP) in new-
born mice (16,17). The anticancer activity of polysaccharides
isolated from Ganoderma lucidum was originally tested in vivo
using sarcoma 180 cells transplanted subcutaneously into mice
(18). The anticancer effects of Ganoderma lucidum were
attributed to the activity of ß-glucans (19), which have also
been isolated from other mushrooms and demonstrate potent
immunostimulatory activity (20). Therefore, the stimulation
of immune effector cells leads to the subsequent production
of cytokines, and contributes to the anticancer activity of
Ganoderma lucidum (19).
Similar to the results obtained using the mouse sarcoma
180 cell model, a polysaccharide extract of Ganoderma
lucidum has also been shown to inhibit the growth of Lewis
lung carcinoma cells in mice (19,21). The sulfate derivatives
of D-glucans demonstrate a significantly higher antitumor
activity against Ehrlich ascites carcinoma (22). Furthermore,
water-soluble extracts from the culture medium of Ganoderma
lucidum prevent azoxymethan-induced aberrant crypt foci
and colon cancer in rats and the development of N,N'-
dimethylhydrazine-induced colon tumors in ICR mice
(11-13). Finally, a Ganoderma lucidum polysaccharide
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Table I. Body weight and organ weight (relative weight).
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Body Heart (g) Thyroid (mg) Lung (g) Liver (g) Kidney (g) Testis (g) Adrenal Spleen (g)
weight (g) gland (mg)
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Normal 498.1±8.9 1.35±0.03 40.0±1.8 1.59±0.04 12.61±0.28 2.51±0.04 3.17±0.15 44.4±1.5 0.94±0.33
(0.27±0.01) (79.9±3.6) (0.32±0.01) (2.53±0.04) (0.51±0.01) (0.64±0.03) (89.4±3.3) (184.3±62.3)
BHP 429.4±16.5a 1.25±0.02 94.9±9.5a 1.65±0.04 11.04±0.21a 2.36±0.05 1.14±0.04a 35.7±1.5a 0.56±0.01
(0.30±0.02) (226.4±24.2a) (0.40±0.02a) (2.65±0.17) (0.56±0.03) (0.27±0.02a) (85.1±5.0) (133.1±8)
BHP+1.25% 448.9±3.8 1.24±0.03 80.6±8.1 1.75±0.04 11.63±0.19 2.48±0.06 1.18±0.06 37.8±1.4 0.57±0.02
MAK (0.28±0.01) (180.3±18.6) (0.39±0.01) (2.59±0.03) (0.55±0.02) (0.26±0.01) (84.1±2.9)   (127.5±5.6)
BHP+2.5% 460.7±12.3 1.29±0.03 22±32.3 2.04±0.24 12.04±0.33 2.62±0.13 1.23±0.13 39.8±2.2 0.78±0.14
MAK (0.28±0.01) (262.7±69.7) (0.47±0.09) (2.63±0.07) (0.59±0.06) (0.27±0.03) (89.1±8.9) (181.4±44.8)
BHP+5% 456.8±4.4 1.29±0.04 96.9±7.6 1.82±0.05 12.24±0.23 2.59±0.04 1.19±0.04 36.7±1.2 0.63±0.03
MAK (0.28±0.01) (212.7±17.2) (0.40±0.01) (2.68±0.04) (0.57±0.01) (0.26±0.01) (80.4±2.6) (137.1±5.3)
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Values are mean ±SE, asignificantly different from the normal value (P<0.01).
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Table II. Number and size of the lung nodules.
–––––––––––––––––––––––––––––––––––––––––––––––––
Group Number Mean diameter
of nodules of nodules
–––––––––––––––––––––––––––––––––––––––––––––––––
BHP 58.7±6.2 3.83±0.07
BHP+1.25% MAK 44.4±4.1 3.33±0.06a
BHP+2.5% MAK 48.1±6 3.15±0.06a
BHP+5% MAK 35.4±4.7a 3.17±0.07a
–––––––––––––––––––––––––––––––––––––––––––––––––
Values are mean ±SE, asignificantly different from the BHP value (P<0.01).
–––––––––––––––––––––––––––––––––––––––––––––––––
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extract (Ganopoly) reportedly stimulates immune function in
patients with advanced cancers, including those of the lung,
colon, breast, liver, prostate, bladder, and the brain (8). Twelve
weeks of treatment with Ganopoly resulted in a significant
increase in the plasma concentrations of IL-2, IL-6 and IFN-Á
and enhanced NK activity, whereas the levels of IL-1 and
TNF-· were significantly decreased (8).
In the present study, by classifying the PCNA index into
four types - negative, slightly positive, positive or strongly
positive - by microscopic observation of 100 random tumors
from five lobules of the lung, MAK was found to decrease
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Figure 1. H&E staining of the lung lesions (x100). (A) Hyperplasia; (B) adenoma; (C) adenocarcinoma; (D) squamous cell carcinoma.
Table III. Tumor incidence.
–––––––––––––––––––––––––––––––––––––––––––––––––
Number of Pulmonary Squamous Thyroid
animals tumors cell tumor
carcinoma
–––––––––––––––––––––––––––––––––––––––––––––––––
Normal 16 0 0 0
BHP 15 15a (100)b 2 (13) 15 (100)
BHP+1.25% 16 16 (100) 1 (6) 16 (100)
MAK
BHP+2.5% 15 15 (100) 3 (20) 15 (100)
MAK
BHP+5% 15 15 (100) 0 15 (100)
MAK
–––––––––––––––––––––––––––––––––––––––––––––––––
aNumber of animals with tumors, bincidence rate.
–––––––––––––––––––––––––––––––––––––––––––––––––
Table IV. Number of pulmonary tumors (per animal).a
–––––––––––––––––––––––––––––––––––––––––––––––––
Group Total pulmonary Adenoma Carcinoma
tumorsb
–––––––––––––––––––––––––––––––––––––––––––––––––
BHP 42.71±3.07 28.43±2.86 14.29±1.27
BHP+1.25% 28.80±2.14c 20.27±1.38c 11.33±1.31
MAK
BHP+2.5% 24.80±1.72c 23±1.90c 9.20±1.20c
MAK
BHP+5% 24.50±2.42c 19.20±2.50c 8.29±1.18c
MAK
–––––––––––––––––––––––––––––––––––––––––––––––––
aData indicate the total number of tumors measured in each section of 5
lobules; badenoma + adenocarcinoma; values are mean ±SE; csignificantly
different from the BHP value (P<0.01).
–––––––––––––––––––––––––––––––––––––––––––––––––
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the number of strongly positive tumors and increase the
number of negative tumors in a dose-dependent manner. In
the present study, MAK attenuated the up-regulated cell
cycle activity during carcinogenesis after exposure to the
carcinogen. As a similar effect has also been reported in an
animal model of colon carcinogenesis (11-13), MAK is
thought to function in this way to achieve its anti-tumor
effect. MAK did not influence the cell cycle of normal tissue
close to carcinoma lesions (data not shown), and this has also
been reported in the colon carcinogenesis animal model.
Accordingly, MAK is thought to have no effect on the
proliferation of normal epithelial cells. In addition, macro-
scopic observation revealed that MAK reduced the number
and size of tumors induced by the carcinogen, and this reflected
the decrease in the number of PCNA-positive carcinomas. A
recent study has shown that for the prevention of tumor
formation it is important to arrest the apoptosis guidance
ability of p53 and the destabilization of the genome, and the
destabilized prevention of a genome may be attained by the
guidance of a cell cycle stop (23). Therefore, it is shown that
MAK counteracts the up-regulation of the cell cycle in
association with proteins such as p53, or contributes to gene
stability. Further study is needed to shed more light on the
function of MAK.
In addition to in vivo biological activities other than
anticancer effects, the intragastric application of poly-
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Table V. Size of the pulmonary tumors (mm).a
–––––––––––––––––––––––––––––––––––––––––––––––––
Group Total pulmonary Adenoma Carcinoma
tumor
–––––––––––––––––––––––––––––––––––––––––––––––––
BHP 1.07±0.03 0.99±0.03 1.23±0.06
BHP+1.25% 1.11±0.04 0.93±0.03 1.37±0.08
MAK
BHP+2.5% 1.06±0.04 0.93±0.03 1.31±0.07
MAK
BHP+5.0% 0.93±0.03b 0.85±0.03b 1.14±0.07
MAK
–––––––––––––––––––––––––––––––––––––––––––––––––
aData indicate the average diameter of the tumors measured in each section
of five lobules; values are mean ±SE; bsignificantly different from the BHP
value (P<0.01).
–––––––––––––––––––––––––––––––––––––––––––––––––
Figure 2. H&E and PCNA staining of the lung lesions (x100). (A) H&E staining on the 5% MAK+BHP group rats; (B) PCNA staining on (A) as classified to
negative; (C) H&E staining on the BHP group rats; (D) PCNA staining on (C) as classified to strong positive.
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saccharide has been shown to prevent indomethacin- and
acetic acid-induced gastric mucosal lesions in rats (24).
The hepatoprotective effects of the Ganoderma lucidum
polysaccharide have also been evaluated in a mouse infection
model utilizing Bacillus Calmette-Guerin (25). Treatment
with the polysaccharide diminished the histological changes
associated with liver injury, such as hemorrhage and necrosis
in the hepatic lobules and the inflammatory infiltration of
lymphocytes and Kupffer cells around the central vein (25).
Glycans known as ganoderan A and B isolated from the
fruiting bodies of Ganoderma lucidum have been shown to
possess hypoglycemic activity (26). Both ganoderans reduced
the plasma glucose levels in normal mice and mice with
alloxan-induced hyperglycemia (26). Ganoderan B increased
the level of insulin in the plasma but did not have any effect
on insulin binding to isolated adipocytes (27). Ganoderan B
also reduced the glycogen content of the liver but had no
influence on total cholesterol and triglyceride levels in the
plasma and liver (27). Polysaccharides isolated from the
fruiting body demonstrate protective effects against alloxan-
induced damage to insulin-producing pancreatic ß cells,
increasing their viability and protecting them from necrosis
(28). A water extract of mycelia has also been assessed for
cardiovascular activity in rabbits and rats, and was found to
decrease systolic and diastolic blood pressure (29). Cao and
Lin observed that Ganoderma lucidum polysaccharides and
peptide inhibited in vivo angiogenesis using the chick chorio-
allantoic membrane assay (9,30).
In an in vivo experiment, oral administration of the triter-
penoid fraction of the fruiting body of Ganoderma lucidum
inhibited the growth of intrasplenic implants of Lewis lung
carcinoma in mice (31). In addition, the triterpenoid fraction
prevented the invasion of metastatic tumor cells into the
white pulp of the spleen and hepatic parenchyma (31).
Furthermore, matrigel-induced neovascularization was also
inhibited, and the biologically active compound responsible
for the suppression of angiogenesis was identified as
ganodric acid F (31). Combined treatment with lovastatin and
an oxygenated triterpenoid fraction from Ganoderma lucidum
inhibited the growth of human hepatoma Hep 3B cells (3).
Moreover, lovastatin and the triterpenoid fraction reduced the
growth of tumors in nude mice with orthotopically inoculated
human hepatoma Hep 3B/T2 cells (25). These data suggest
that triterpenoids from Ganoderma lucidum may have
potential as an adjuvant therapy for the treatment of cancer.
All of the above studies clearly show that Ganoderma lucidum
possesses antitumor and immunomodulatory potential.
In conclusion, the results of the present study indicate that
Ganoderma lucidum may be a useful chemopreventive agent,
and that further study is warranted to identify the active
component involved in its effect. Studies are now in progress
in our laboratory to further clarify the active compounds in
the water-soluble extract and investigate their pharmaceutical
effects.
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